1. Home
  2. TVRD vs DETX Comparison

TVRD vs DETX Comparison

Compare TVRD & DETX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Tvardi Therapeutics Inc.

TVRD

Tvardi Therapeutics Inc.

SELL

Current Price

$1.09

Market Cap

15.7M

Sector

Health Care

ML Signal

SELL

Logo Liberty Defense Holdings Ltd. Common Shares

DETX

Liberty Defense Holdings Ltd. Common Shares

SELL

Current Price

$0.94

Market Cap

14.8M

ML Signal

SELL

Company Overview

Basic Information
Metric
TVRD
DETX
Founded
2017
2012
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Telecommunications Equipment
Sector
Health Care
Telecommunications
Exchange
Nasdaq
Nasdaq
Market Cap
15.7M
14.8M
IPO Year
2013
2022

Fundamental Metrics

Financial Performance
Metric
TVRD
DETX
Price
$1.09
$0.94
Analyst Decision
Buy
Analyst Count
9
0
Target Price
★ $8.88
N/A
AVG Volume (30 Days)
★ 207.0K
16.6K
Earning Date
11-13-2026
11-27-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 79.01
N/A
EPS
N/A
★ N/A
Revenue
★ $911,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
★ 959.30
N/A
52 Week Low
$0.77
$1.15
52 Week High
$5.69
$4.25

Technical Indicators

Market Signals
Indicator
TVRD
DETX
Relative Strength Index (RSI) 50.87 21.93
Support Level $0.85 N/A
Resistance Level $2.02 $1.83
Average True Range (ATR) 0.17 0.18
MACD 0.05 -0.01
Stochastic Oscillator 41.46 5.10

Price Performance

Historical Comparison
TVRD
DETX

About TVRD Tvardi Therapeutics Inc.

Tvardi Therapeutics Inca clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting Signal Transducer and Activator of Transcription 3 (STAT3) to treat inflammatory and proliferative diseases with unmet need. Its pipeline includes two oral, small molecule STAT3 inhibitors: TTI-101 and TTI-109. TTI-101 is its first-generation direct STAT3 inhibitor, currently in Phase 1b/2 clinical development in hepatocellular carcinoma (HCC). TTI-109 is a phosphate prodrug of TTI-101 that is mechanistically identical to its parent molecule but is designed to enhance its ability to target STAT3.

About DETX Liberty Defense Holdings Ltd. Common Shares

Liberty Defense Holdings Ltd is engaged in the development and commercialization of security detection technologies such as airports, stadiums, schools, and more. The company's Hexwave product utilizes millimeter wave technology and Advanced 3D imaging to detect concealed threats. In addition to HEXWAVE, the company has licensed High-Definition Advanced Imaging Technology (HD-AIT) for body and shoe scanning. The Company operates through three distinct segments: Corporate, HEXWAVE, and Contract. The company generates the majority of its revenue from the Contract segment. Geographically, the company generates the majority of its revenue from the United States.

Share on Social Networks: